iTeos Therapeutics, Inc.
ITOS
$7.19
-$0.33-4.39%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.50% | -2.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.30% | 0.73% | |||
| Operating Income | 0.30% | -266.35% | |||
| Income Before Tax | 15.67% | -785.86% | |||
| Income Tax Expenses | 227.91% | -0.80% | |||
| Earnings from Continuing Operations | 3.63% | -536.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.63% | -536.34% | |||
| EBIT | 0.30% | -266.35% | |||
| EBITDA | 0.34% | -272.78% | |||
| EPS Basic | 3.73% | -485.47% | |||
| Normalized Basic EPS | 15.77% | -715.54% | |||
| EPS Diluted | 3.63% | -484.17% | |||
| Normalized Diluted EPS | 15.77% | -715.54% | |||
| Average Basic Shares Outstanding | 0.10% | 8.66% | |||
| Average Diluted Shares Outstanding | 0.10% | 8.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
